14.

Income Taxes:

Since the Company has recurring losses and a valuation allowance against deferred tax assets, there is no tax expense (benefit) for the year ended 2017. For the year ended December 31, 2018, the Company recognized a tax benefit of $(474,391).

The subsidiaries each file separate tax returns in their respective tax jurisdictions.

As of December 31, 2018, the Company had federal and state net operating loss (“NOL”) carryforwards in the United States of approximately $14,210,000 and $14,155,000, respectively, and in the United Kingdom of approximately $94,100,000, which are available to reduce future taxable income. The U.S. federal and state NOL carry forwards incurred prior to January 1, 2018 in the amount of approximately $6.8 million and $6.7 million, respectively, will begin to expire in 2036. The U.S. NOL incurred after December 31, 2018 and the U.K. NOL will be indefinitely carried forward. Also, as of December 31, 2018, the Company had orphan drug and research and development credits in the U.S. in the amount of $1,134,000 which will begin to expire in 2036. The NOL carry forwards are subject to review and possible adjustment by the U.S., U.K. and state tax authorities. NOL carry forwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders, as defined under Sections 382 Internal Revenue Code, as well as CTA 2010 Part 14 under the UK tax rules. This could limit the amount of NOLs that the Company can utilize annually to offset future taxable income or tax liabilities. As of December 31, 2018, the Company has performed such an analysis and determined that there were no limitations in the U.K. However, for U.S. purposes the Company determined that a change of ownership occurred in April 2016. The Company is still in the process of determining the annual limitation on losses that occurred prior to April 2016. Subsequent ownership changes and proposed future changes to the UK (or US) tax rules in respect of the utilization of losses carried forward may further affect the limitation in future years, if any. Additionally, the Company has not undertaken a study on the completeness of the U.S. orphan drug and research and development credit.

The Company’s pre tax earnings from the United Kingdom and United States locations are as follows:


	December 31, 2018			December 31, 2017
United Kingdom	$	(73,359,977	)	$	(26,458,625	)
United States		(9,980,287	)		(4,585,910	)

	$	(83,340,264	)	$	(31,044,535	)

The Company is subject to the corporate tax rate in the U.K. as a Limited U.K. corporation.

The following table summarizes a reconciliation of income tax benefit compared with the amounts at the U.K. statutory income tax rate:


	December 31, 2018					December 31, 2017
Statutory rate		(15,834,650	)	19.00	%		(5,976,073	)	19.25	%
Permanent differences—other		1,438,934		-1.73	%		654,648		-2.11	%
RTP and other adjustments		387,509		-0.46	%		(152,948	)	0.49	%
U.K. tax credit		1,707,489		-2.05	%		539,136		-1.74	%
U.S. tax credit		(436,250	)	0.52	%		(363,665	)	1.17	%
Foreign tax rate differential		(171,693	)	0.21	%		(673,619	)	2.17	%
State and local rate, net of federal tax		(1,159,522	)	1.39	%		(446,683	)	1.44	%
UK Rate Change (17% at expected DTA turn)		1,104,863		-1.33	%		482,351		-1.55	%
U.S. state rate change		(6,496	)	0.01	%		993,998		-3.20	%
Change in valuation allowance		12,495,426		-14.99	%		4,942,855		-15.92	%

Actual income tax benefit effective tax rate		(474,391	)	0.57	%		—		0.00	%

The Expense/(Benefit) for income taxes from continuing operations consists of the following:


	December 31, 2018			December 31, 2017
Current Tax Expense/(Benefit)
United Kingdom		—			—
United States		—			—

Total Current		—			—
Deferred Tax Expense/(Benefit)
United Kingdom	$	(8,888,096	)	$	(3,759,109	)
United States		(3,606,275	)		(1,183,746	)

Total Deferred		(12,494,371	)		(4,942,855	)
Change in Valuation Allowance		12,019,880			4,942,855

Total Income Tax Expense/(Benefit)	$	(474,391	)	$	—

Income tax (benefit) expense for each year is allocated to continuing operations, discontinued operations, extraordinary items, other comprehensive income, the cumulative effects of accounting changes, and other charges or credits recorded directly to shareholders’ equity. ASC 740-20-45 Income Taxes, Intraperiod Tax Allocation, Other Presentation Matters includes an exception to the general principle of intraperiod tax allocations. The codification source states that the tax effect of pretax income or loss from continuing operations generally should be determined by a computation that considers only the tax effects of items that are included in continuing operations. The exception to that incremental approach is that all items (i.e. other comprehensive income, discontinued operations, etc.) be considered in determining the amount of tax benefit that results from a loss from continuing operations and that benefit should be allocated to continuing operations. That is, when a company has a current period loss from continuing operations, management must consider income recorded in other categories in determining the tax benefit that is allocated to continuing operations. This includes situations in which a company has recorded a full valuation allowance at the beginning and end of the period, and the overall tax provision for the year is zero. The intraperiod tax allocation is performed once the overall tax provision has been computed and allocates that provision to various income statement (continuing operations, discontinued operations), other comprehensive income and balance sheet captions. While the intraperiod tax allocation does not change the overall tax provision, it results in a gross-up of the individual components. The level of application has been applied on the group level.

As the Company experienced a net loss from operations for the year ended December 31, 2018 and other comprehensive income from foreign currency translation adjustments, the Company has allocated income tax expense against the components of other comprehensive income in 2018 using a 17% effective tax rate. Income tax benefit for the year ended December 31, 2018 includes a benefit of $(474,391) due to the required intraperiod tax allocation. Conversely, other comprehensive income for the year ended December 31, 2018 includes income tax expense of $474,391.

Deferred Tax Assets/(Liabilities)


	December 31, 2018
	Total			UK			US
Deferred Tax Assets:
Net operating loss carryforwards	$	20,646,185		$	16,000,329		$	4,645,856
Other		1,414,690			(46,604	)		1,461,294
Tax Credit		1,133,656			—			1,133,656

Deferred tax assets		23,194,531			15,953,725			7,240,806
Less: valuation allowance		(23,194,531	)		(15,953,725	)		(7,240,806	)

Net deferred tax asset	$	—		$	—		$	—


	December 31, 2017
	Total			UK			US
Deferred Tax Assets:
Net operating loss carryforwards	$	9,462,690		$	6,909,754		$	2,552,937
Other		539,008			152,554			386,454
Tax Credit		697,406			—			697,406

Deferred tax assets		10,699,105			7,062,308			3,636,797
Less: valuation allowance		(10,699,105	)		(7,062,308	)		(3,636,797	)

Net deferred tax asset	$	—		$	—		$	—

ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a full valuation allowance against its deferred tax assets at December 31, 2018 and 2017 because the Company’s management has determined that is it more likely than not that these assets will not be fully realized.

Changes to the U.K. and U.S. corporation tax rates have been announced which will impact future accounting periods. In his budget of July 8, 2015, the Chancellor of the Exchequer announced a reduction in the U.K. corporation tax rate to 19% for the financial year beginning April 1, 2017 and a further reduction to 18% for the financial year beginning April 1, 2020. These changes received Royal Assent on November 18, 2015. The U.K. Finance Act 2016 provides for a further reduction in the corporation tax rate to 17% for the Financial Year beginning April 1, 2020. This change was enacted on September 15, 2016. As the Company does not expect to be able to utilize its NOL’s in the U.K. prior to its financial year beginning on January 1, 2021, if at all, the deferred tax has been calculated using a tax rate of 17%.

In the United States, the corporation tax rate was reduced to 21% for the financial year beginning January 1, 2018. As these changes were enacted prior to the December 31, 2017 balance sheet date, deferred tax has been calculated accordingly in these consolidated financial statements, which represented a decrease in the prior years deferred tax assets of approximately $994,000.

The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2018 and 2017, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s statements of operations and comprehensive loss.

The Company files income tax returns in the United States, United Kingdom and the Netherlands, and various state jurisdictions. For the US, the statute of examination is open for tax years 2015, 2016, 2017 and 2018. For the UK and the Netherlands, the statute of examination is open for tax years 2017 and 2018.

MeiraGTx Holdings plc is a UK tax resident with no earnings in its foreign subsidiaries and the Company does not expect any temporary basis difference in its investment in these subsidiaries to reverse in the foreseeable future. Therefore, the Company has not recorded deferred taxes on the outside basis difference in its foreign subsidiaries. It is not probable to compute the amounts, if any.